Assessment superseded
Metformin tested in RCT to prevent frailty in high-risk older adults; results not reported
This abstract describes an RCT designed to test whether metformin prevents or reduces frailty progression in high-risk older adults by modulating diabetes, insulin resistance, and inflammation. No results, sample size, or effect sizes are provided in the available material.
RCTN=125Notable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 6, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 125
- Duration
- 24 months
- Population
- High-risk older adults; mean age 71-72 years; 48% female (68/141 at baseline); 93% White, 4% African American, 2% Other; 35% Hispanic or Latino
- Primary outcome
- Fried Frailty Phenotype Criteria: covariate adjusted monthly rate of change in Fried frailty score (range 0-5) from baseline to 2 years. Metformin: 0.0289 (SE 0.0049); Placebo: 0.0164 (SE 0.0058)
- Effect size
- Primary outcome - Metformin: 0.0289 (SE 0.0049); Placebo: 0.0164 (SE 0.0058). Secondary outcome - Metformin: -0.0002 (SE 0.0002); Placebo: 0.0002 (SE 0.0002)
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Oct 15, 2026
Sources
Primary source
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.